{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:57:23Z","timestamp":1790884643435,"version":"4.1.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Aluminum toxicity in rodents is well documented to be used for inducing experimental models that mimic the clinical phenotypes of Alzheimer\u2019s disease (AD). Liraglutide is a well-known antidiabetic drug promising for modulating neurodegenerative conditions. Thus, investigating the ameliorative effects of Liraglutide on AD induced by aluminum chloride (AlCl\n                    <jats:sub>3<\/jats:sub>\n                    ), highlighting the role of lysophosphatidic acid (LPA)\/ \u03b2-secretase 1 (BACE1), is promising. Male rats are subdivided into four groups. Except for the normal group, animals are subjected to daily administration of AlCl\n                    <jats:sub>3<\/jats:sub>\n                    (70\u2009mg\/kg, i.p.) for 45 days. Along with AlCl\n                    <jats:sub>3<\/jats:sub>\n                    , Liraglutide (0.3\u2009mg\/kg twice daily, s.c.) and Donepezil (1\u2009mg\/kg daily, i.p.) therapy are administered in AlCl3 + Lira and AlCl\n                    <jats:sub>3<\/jats:sub>\n                    + Done groups, respectively. Liraglutide significantly ameliorates AlCl\n                    <jats:sub>3<\/jats:sub>\n                    -induced anxiety, depression-like behaviors, and deficits in memory functions. Liraglutide therapy retains the histopathological structure of the brain, with antioxidant and anti-apoptotic abilities. Moreover, Liraglutide successfully decreases hippocampal levels of oxidized low-density lipoprotein (oxLDL), LPA, lysophosphatidic acid receptor 1 (LPAR1), and \u03b2-secretase 1 (BACE1) compared with the AlCl\n                    <jats:sub>3<\/jats:sub>\n                    group. Thus, liraglutide shows neuroprotective effects mediated by downregulation of the oxLDL\/LPA\/LPAR1\/BACE1 pathway, which is studied for the first time to our knowledge.\n                  <\/jats:p>","DOI":"10.1038\/s42003-026-09531-z","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T13:17:26Z","timestamp":1770815846000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Liraglutide attenuates aluminum chloride-induced Alzheimer\u2019s disease in rats by modulating the oxLDL\/LPA\/LPAR1 pathway"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2896-2802","authenticated-orcid":false,"given":"Nada F.","family":"Abo El-Magd","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8849-7354","authenticated-orcid":false,"given":"Nehal M.","family":"Ramadan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salma M.","family":"Eraky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"9531_CR1","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1126\/science.1074069","volume":"298","author":"DJ Selkoe","year":"2002","unstructured":"Selkoe, D. J. Alzheimer\u2019s disease is a synaptic failure. Science 298, 789\u2013791 (2002).","journal-title":"Science"},{"key":"9531_CR2","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1080\/01616412.2018.1441776","volume":"40","author":"YS Abulfadl","year":"2018","unstructured":"Abulfadl, Y. S., El-Maraghy, N. N., Ahmed, A. A. E., Nofal, S. & Badary, O. A. Protective effects of thymoquinone on D-galactose and aluminum chloride induced neurotoxicity in rats: biochemical, histological and behavioral changes. Neurol. Res. 40, 324\u2013333 (2018).","journal-title":"Neurol. Res."},{"key":"9531_CR3","unstructured":"Dementia: key facts. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/dementia."},{"key":"9531_CR4","unstructured":"Gauthier, S., Neto, P. R., Morais, J. A., Webster, C. World Alzheimer Report 2021: Journey through the diagnosis of dementia (Alzheimer's Disease International, 2021)."},{"key":"9531_CR5","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.bbr.2009.07.012","volume":"205","author":"A Kumar","year":"2009","unstructured":"Kumar, A., Dogra, S. & Prakash, A. Protective effect of curcumin (Curcuma longa), against aluminium toxicity: possible behavioral and biochemical alterations in rats. Behav. Brain Res. 205, 384\u2013390 (2009).","journal-title":"Behav. Brain Res."},{"key":"9531_CR6","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.bcp.2013.12.024","volume":"88","author":"C Reitz","year":"2014","unstructured":"Reitz, C. & Mayeux, R. Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem. Pharmacol. 88, 640\u2013651 (2014).","journal-title":"Biochem. Pharmacol."},{"key":"9531_CR7","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/jnr.10877","volume":"75","author":"A Campbell","year":"2004","unstructured":"Campbell, A., Becaria, A., Lahiri, D. K., Sharman, K. & Bondy, S. C. Chronic exposure to aluminum in drinking water increases inflammatory parameters selectively in the brain. J. Neurosci. Res. 75, 565\u2013572 (2004).","journal-title":"J. Neurosci. Res."},{"key":"9531_CR8","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/978-3-319-60189-2_9","volume":"18","author":"MT Colomina","year":"2017","unstructured":"Colomina, M. T. & Peris-Sampedro, F. Aluminum and Alzheimer\u2019s disease. Adv. Neurobiol. 18, 183\u2013197 (2017).","journal-title":"Adv. Neurobiol."},{"key":"9531_CR9","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.2337\/db13-1954","volume":"63","author":"FG De Felice","year":"2014","unstructured":"De Felice, F. G. & Ferreira, S. T. Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease. Diabetes 63, 2262\u20132272 (2014).","journal-title":"Diabetes"},{"key":"9531_CR10","doi-asserted-by":"publisher","unstructured":"M. A. Camkurt, L. Lavagnino, X. Y. Zhang, A. L. T. Liraglutide for psychiatric disorders: clinical evidence and challenges. Horm. Mol. Biol. Clin. Investig. 36, https:\/\/doi.org\/10.1515\/hmbci-2018-0031 (2018).","DOI":"10.1515\/hmbci-2018-0031"},{"key":"9531_CR11","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.3233\/JAD-191068","volume":"74","author":"L Li","year":"2020","unstructured":"Li, L., Cavuoto, M., Biddiscombe, K., Pike, K. E. & Ravona-Springer, R. Diabetes mellitus increases risk of incident dementia in APOE\u025b4 carriers: a meta-analysis. J. Alzheimer\u2019s. Dis. 74, 1295\u20131308 (2020).","journal-title":"J. Alzheimer\u2019s. Dis."},{"key":"9531_CR12","volume":"13","author":"H Du","year":"2022","unstructured":"Du, H., Meng, X., Yao, Y. & Xu, J. The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer\u2019s disease. Front. Endocrinol. 13, 1033479 (2022).","journal-title":"Front. Endocrinol."},{"key":"9531_CR13","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2020.104707","volume":"135","author":"A Akhtar","year":"2020","unstructured":"Akhtar, A. & Sah, S. P. Insulin signaling pathway and related molecules: Role in neurodegeneration and Alzheimer\u2019s disease. Neurochem. Int. 135, 104707 (2020).","journal-title":"Neurochem. Int."},{"key":"9531_CR14","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/S1474-4422(20)30231-3","volume":"19","author":"D Kellar","year":"2020","unstructured":"Kellar, D. & Craft, S. Brain insulin resistance in Alzheimer\u2019s disease and related disorders: mechanisms and therapeutic approaches. Lancet Neurol. 19, 758\u2013766 (2020).","journal-title":"Lancet Neurol."},{"key":"9531_CR15","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.3390\/ijms21093165","volume":"21","author":"TT Nguyen","year":"2020","unstructured":"Nguyen, T. T., Ta, Q. T. H., Nguyen, T. K. O., Nguyen, T. T. D. & Van Giau, V. Type 3 diabetes and its role implications in Alzheimer\u2019s disease. Int. J. Mol. Sci. 21, 3165 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"9531_CR16","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1007\/s12264-018-00336-7","volume":"35","author":"Y Zhang","year":"2019","unstructured":"Zhang, Y. et al. Liraglutide ameliorates hyperhomocysteinemia-induced Alzheimer-like pathology and memory deficits in rats via multi-molecular targeting. Neurosci. Bull. 35, 724\u2013734 (2019).","journal-title":"Neurosci. Bull."},{"key":"9531_CR17","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/jnr.22565","volume":"89","author":"A Hamilton","year":"2011","unstructured":"Hamilton, A., Patterson, S., Porter, D., Gault, V. A. & Holscher, C. Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain. J. Neurosci. Res. 89, 481\u2013489 (2011).","journal-title":"J. Neurosci. Res."},{"key":"9531_CR18","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.3390\/ijms21051746","volume":"21","author":"AI Duarte","year":"2020","unstructured":"Duarte, A. I. et al. Liraglutide protects against brain amyloid-\u03b21\u201342 accumulation in female mice with early Alzheimer\u2019s disease-like pathology by partially rescuing oxidative\/nitrosative stress and inflammation. Int. J. Mol. Sci. 21, 1746 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"9531_CR19","doi-asserted-by":"crossref","first-page":"326","DOI":"10.2174\/1570159X14666151208112754","volume":"14","author":"YYS Jennifer","year":"2016","unstructured":"Jennifer, Y. Y. S. & Simon, J. G. L. Current treatment options for Alzheimer\u2019s disease and Parkinson\u2019s disease dementia. Curr. Neuropharmacol. 14, 326\u2013338 (2016).","journal-title":"Curr. Neuropharmacol."},{"key":"9531_CR20","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108352","volume":"190","author":"G Marucci","year":"2021","unstructured":"Marucci, G. et al. Efficacy of acetylcholinesterase inhibitors in Alzheimer\u2019s disease. Neuropharmacology 190, 108352 (2021).","journal-title":"Neuropharmacology"},{"key":"9531_CR21","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1093\/brain\/awl251","volume":"129","author":"CL Masters","year":"2006","unstructured":"Masters, C. L. & Beyreuther, K. Alzheimer\u2019s centennial legacy: prospects for rational therapeutic intervention targeting the A\u03b2 amyloid pathway. Brain 129, 2823\u20132839 (2006).","journal-title":"Brain"},{"key":"9531_CR22","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1001\/archneur.59.9.1381","volume":"59","author":"H Fukumoto","year":"2002","unstructured":"Fukumoto, H., Cheung, B. S., Hyman, B. T. & Irizarry, M. C. \u03b2-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch. Neurol. 59, 1381\u20131389 (2002).","journal-title":"Arch. Neurol."},{"key":"9531_CR23","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/ana.10208","volume":"51","author":"RMD Holsinger","year":"2002","unstructured":"Holsinger, R. M. D., McLean, C. A., Beyreuther, K., Masters, C. L. & Evin, G. Increased expression of the amyloid precursor \u03b2-secretase in Alzheimer\u2019s disease. Ann. Neurol. 51, 783\u2013786 (2002).","journal-title":"Ann. Neurol."},{"key":"9531_CR24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/nm0103-3","volume":"9","author":"L-B Yang","year":"2003","unstructured":"Yang, L.-B. et al. Elevated \u03b2-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat. Med. 9, 3\u20134 (2003).","journal-title":"Nat. Med."},{"key":"9531_CR25","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1111\/j.1742-4658.2009.06929.x","volume":"276","author":"CE Hunt","year":"2009","unstructured":"Hunt, C. E. & Turner, A. J. Cell biology, regulation and inhibition of \u03b2-secretase (BACE-1). FEBS J. 276, 1845\u20131859 (2009).","journal-title":"FEBS J."},{"key":"9531_CR26","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.plipres.2011.06.001","volume":"50","author":"V Frisardi","year":"2011","unstructured":"Frisardi, V., Panza, F., Seripa, D., Farooqui, T. & Farooqui, A. A. Glycerophospholipids and glycerophospholipid-derived lipid mediators: a complex meshwork in Alzheimer\u2019s disease pathology. Prog. Lipid Res. 50, 313\u2013330 (2011).","journal-title":"Prog. Lipid Res."},{"key":"9531_CR27","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.bbadis.2012.09.010","volume":"1832","author":"J Shi","year":"2013","unstructured":"Shi, J., Dong, Y., Cui, M.-Z. & Xu, X. Lysophosphatidic acid induces increased BACE1 expression and A\u03b2 formation. Biochim. Biophys. Acta 1832, 29\u201338 (2013).","journal-title":"Biochim. Biophys. Acta"},{"key":"9531_CR28","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/BF02870187","volume":"33","author":"B Draczynska-Lusiak","year":"1998","unstructured":"Draczynska-Lusiak, B., Doung, A. & Sun, A. Y. Oxidized lipoproteins may play a role in neuronal cell death in Alzheimer disease. Mol. Chem. Neuropathol. 33, 139\u2013148 (1998).","journal-title":"Mol. Chem. Neuropathol."},{"key":"9531_CR29","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00580-015-2182-0","volume":"25","author":"OME Abdel-Salam","year":"2016","unstructured":"Abdel-Salam, O. M. E. et al. Effect of piracetam, vincamine, vinpocetine, and donepezil on oxidative stress and neurodegeneration induced by aluminum chloride in rats. Comp. Clin. Pathol. 25, 305\u2013318 (2016).","journal-title":"Comp. Clin. Pathol."},{"key":"9531_CR30","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.ijbiomac.2022.11.291","volume":"227","author":"SM Eraky","year":"2023","unstructured":"Eraky, S. M., Ramadan, N. M. & Abo El-Magd, N. F. Ameliorative effects of bromelain on aluminum-induced Alzheimer\u2019s disease in rats through modulation of TXNIP pathway. Int. J. Biol. Macromol. 227, 1119\u20131131 (2023).","journal-title":"Int. J. Biol. Macromol."},{"key":"9531_CR31","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.metabol.2012.03.002","volume":"61","author":"H Hendarto","year":"2012","unstructured":"Hendarto, H. et al. GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases. Metab. Clin. Exp. 61, 1422\u20131434 (2012).","journal-title":"Metab. Clin. Exp."},{"key":"9531_CR32","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.biopha.2017.05.086","volume":"92","author":"HH Gaballah","year":"2017","unstructured":"Gaballah, H. H., Zakaria, S. S., Mwafy, S. E., Tahoon, N. M. & Ebeid, A. M. Mechanistic insights into the effects of quercetin and\/or GLP-1 analogue liraglutide on high-fat diet\/streptozotocin-induced type 2 diabetes in rats. Biomed. Pharmacother. 92, 331\u2013339 (2017).","journal-title":"Biomed. Pharmacother."},{"key":"9531_CR33","volume":"8","author":"NM Abd El-Rady","year":"2021","unstructured":"Abd El-Rady, N. M., Ahmed, A., Abdel-Rady, M. M. & Ismail, O. I. Glucagon-like peptide-1 analog improves neuronal and behavioral impairment and promotes neuroprotection in a rat model of aluminum-induced dementia. Physiol. Rep. 8, e14651 (2021).","journal-title":"Physiol. Rep."},{"key":"9531_CR34","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s00210-016-1269-8","volume":"389","author":"K Gawel","year":"2016","unstructured":"Gawel, K. et al. Cholinesterase inhibitors, donepezil and rivastigmine, attenuate spatial memory and cognitive flexibility impairment induced by acute ethanol in the Barnes maze task in rats. Naunyn Schmiedeb. Arch. Pharmacol. 389, 1059\u20131071 (2016).","journal-title":"Naunyn Schmiedeb. Arch. Pharmacol."},{"key":"9531_CR35","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.neubiorev.2010.10.016","volume":"35","author":"DC Blanchard","year":"2011","unstructured":"Blanchard, D. C., Griebel, G., Pobbe, R. & Blanchard, R. J. Risk assessment as an evolved threat detection and analysis process. Neurosci. Biobehav. Rev. 35, 991\u2013998 (2011).","journal-title":"Neurosci. Biobehav. Rev."},{"key":"9531_CR36","doi-asserted-by":"crossref","unstructured":"Rodriguez, A. et al. ToxTrac: a fast and robust software for tracking organisms. Methods Ecol. Evol. 9, 460\u2013464 (2018).","DOI":"10.1111\/2041-210X.12874"},{"key":"9531_CR37","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s13195-020-00705-3","volume":"12","author":"D Cutuli","year":"2020","unstructured":"Cutuli, D. et al. Behavioral, neuromorphological, and neurobiochemical effects induced by omega-3 fatty acids following basal forebrain cholinergic depletion in aged mice. Alzheimer\u2019s. Res. Ther. 12, 150 (2020).","journal-title":"Alzheimer\u2019s. Res. Ther."},{"key":"9531_CR38","volume":"195","author":"NEA Khalaf","year":"2020","unstructured":"Khalaf, N. E. A. et al. Clopidogrel combats neuroinflammation and enhances learning behavior and memory in a rat model of Alzheimer\u2019s disease. Pharmacol. Biochem. Behav. 195, 172956 (2020).","journal-title":"Pharmacol. Biochem. Behav."},{"key":"9531_CR39","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13195-020-00639-w","volume":"12","author":"Y Zhao","year":"2020","unstructured":"Zhao, Y. et al. Young blood plasma reduces Alzheimer\u2019s disease-like brain pathologies and ameliorates cognitive impairment in 3\u00d7Tg-AD mice. Alzheimer\u2019s. Res. Ther. 12, 70 (2020).","journal-title":"Alzheimer\u2019s. Res. Ther."},{"key":"9531_CR40","doi-asserted-by":"crossref","unstructured":"Delgado, N.M., Popovi\u0107, N., De la Cruz-S\u00e1nchez, E., Bleda, M. C., Popovi\u0107, M. Time-of-day and age impact on memory in elevated plus-maze test in rats. Front. Behav. Neurosci. 12, 304 (2018).","DOI":"10.3389\/fnbeh.2018.00304"},{"key":"9531_CR41","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00213-005-0052-1","volume":"182","author":"MM Campos","year":"2005","unstructured":"Campos, M. M., Fernandes, E. S., Ferreira, J., Santos, A. R. & Calixto, J. B. Antidepressant-like effects of Trichilia catigua (Catuaba) extract: evidence for dopaminergic-mediated mechanisms. Psychopharmacology 182, 45\u201353 (2005).","journal-title":"Psychopharmacology"},{"key":"9531_CR42","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1038\/nprot.2006.170","volume":"1","author":"RMJ Deacon","year":"2006","unstructured":"Deacon, R. M. J. Assessing nest building in mice. Nat. Protoc. 1, 1117\u20131119 (2006).","journal-title":"Nat. Protoc."},{"key":"9531_CR43","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/j.1471-4159.1966.tb09873.x","volume":"13","author":"J Glowinski","year":"1966","unstructured":"Glowinski, J. & Iversen, L. L. Regional studies of catecholamines in the rat brain. I. The disposition of [3H]norepinephrine, [3H]dopamine and [3H]dopa in various regions of the brain. J. Neurochem. 13, 655\u2013669 (1966).","journal-title":"J. Neurochem."},{"key":"9531_CR44","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s004010000248","volume":"101","author":"S Litchfield","year":"2001","unstructured":"Litchfield, S. & Nagy, Z. New temperature modification makes the Bielschowsky silver stain reproducible. Acta Neuropathol. 101, 17\u201321 (2001).","journal-title":"Acta Neuropathol."},{"key":"9531_CR45","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead, P. et al. QuPath: open source software for digital pathology image analysis. Sci. Rep. 7, 16878 (2017).","journal-title":"Sci. Rep."},{"key":"9531_CR46","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0165-0270(84)90007-4","volume":"11","author":"R Morris","year":"1984","unstructured":"Morris, R. Developments of a water-maze procedure for studying spatial learning in the rat. J. Neurosci. Methods 11, 47\u201360 (1984).","journal-title":"J. Neurosci. Methods"},{"key":"9531_CR47","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0165-0173(01)00067-4","volume":"36","author":"R D\u2019Hooge","year":"2001","unstructured":"D\u2019Hooge, R. & De Deyn, P. P. Applications of the Morris water maze in the study of learning and memory. Brain Res. Brain Res. Rev. 36, 60\u201390 (2001).","journal-title":"Brain Res. Brain Res. Rev."},{"key":"9531_CR48","doi-asserted-by":"crossref","unstructured":"Bakhshwin, D. M. et al. Neuroprotective effect of liraglutide and memantine in a rat model of Alzheimer\u2019s disease. Asian Pac. J. Trop. Biomed. 14, 207\u2013214 (2024).","DOI":"10.4103\/apjtb.apjtb_937_23"},{"key":"9531_CR49","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/sj.bjp.0706927","volume":"149","author":"J Meunier","year":"2006","unstructured":"Meunier, J., Ieni, J. & Maurice, T. The anti-amnesic and neuroprotective effects of donepezil against amyloid \u03b225-35 peptide-induced toxicity in mice involve an interaction with the \u03c31 receptor. Br. J. Pharmacol. 149, 998\u20131012 (2006).","journal-title":"Br. J. Pharmacol."},{"key":"9531_CR50","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1517\/17425255.4.10.1363","volume":"4","author":"SA Jacobson","year":"2008","unstructured":"Jacobson, S. A. & Sabbagh, M. N. Donepezil: potential neuroprotective and disease-modifying effects. Expert Opin. Drug Metab. Toxicol. 4, 1363\u20131369 (2008).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"9531_CR51","doi-asserted-by":"crossref","first-page":"4224","DOI":"10.1111\/bph.14030","volume":"174","author":"SH Kim","year":"2017","unstructured":"Kim, S. H. et al. Beyond symptomatic effects: potential of donepezil as a neuroprotective agent and disease modifier in Alzheimer\u2019s disease. Br. J. Pharmacol. 174, 4224\u20134232 (2017).","journal-title":"Br. J. Pharmacol."},{"key":"9531_CR52","volume":"8","author":"P Fan","year":"2020","unstructured":"Fan, P., Ning, J. & Yuxiu, L. Association between metformin and neurodegenerative diseases of observational studies: systematic review and meta-analysis. BMJ Open Diab. Res. Care 8, e001370 (2020).","journal-title":"BMJ Open Diab. Res. Care"},{"key":"9531_CR53","doi-asserted-by":"crossref","first-page":"706","DOI":"10.14283\/jpad.2023.113","volume":"10","author":"M Tahmi","year":"2023","unstructured":"Tahmi, M. & Luchsinger, J. A. Metformin in the prevention of Alzheimer\u2019s disease and Alzheimer\u2019s disease related dementias. J. Prev. Alzheimer\u2019s. Dis. 10, 706\u2013717 (2023).","journal-title":"J. Prev. Alzheimer\u2019s. Dis."},{"key":"9531_CR54","doi-asserted-by":"crossref","first-page":"7504","DOI":"10.1523\/JNEUROSCI.23-20-07504.2003","volume":"23","author":"Q Yan","year":"2003","unstructured":"Yan, Q. et al. Anti-inflammatory drug therapy alters \u03b2-amyloid processing and deposition in an animal model of Alzheimer\u2019s disease. J. Neurosci. 23, 7504\u20137509 (2003).","journal-title":"J. Neurosci."},{"key":"9531_CR55","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1093\/brain\/awh452","volume":"128","author":"MT Heneka","year":"2005","unstructured":"Heneka, M. T. et al. Acute treatment with the PPAR\u03b3 agonist pioglitazone and ibuprofen reduces glial inflammation and A\u03b21\u201342 levels in APPV717I transgenic mice. Brain 128, 1442\u20131453 (2005).","journal-title":"Brain"},{"key":"9531_CR56","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.trci.2019.09.010","volume":"5","author":"DK Burns","year":"2019","unstructured":"Burns, D. K. et al. The TOMMORROW study: design of an Alzheimer's disease delay-of-onset clinical trial. Alzheimer\u2019s. Dement. 5, 661\u2013670 (2019).","journal-title":"Alzheimer\u2019s. Dement."},{"key":"9531_CR57","volume":"13","author":"MJ Carranza-Naval","year":"2021","unstructured":"Carranza-Naval, M. J. et al. Liraglutide reduces vascular damage, neuronal loss, and cognitive impairment in a mixed Murine model of Alzheimer\u2019s disease and Type 2 diabetes. Front. Aging Neurosci. 13, 741923 (2021).","journal-title":"Front. Aging Neurosci."},{"key":"9531_CR58","doi-asserted-by":"crossref","unstructured":"Christopher Kwon, Y. I. et al. \u03b3-Glutamyl-transpeptidase-resistant glutathione analog attenuates progression of Alzheimer\u2019s disease-like pathology and neurodegeneration in a mouse model. Antioxidants 10, 1796 (2021).","DOI":"10.3390\/antiox10111796"},{"key":"9531_CR59","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2019.06.001","volume":"310","author":"C Zheng","year":"2019","unstructured":"Zheng, C. et al. The protective effects of liraglutide on AD-like neurodegeneration induced by oxidative stress in human neuroblastoma SH-SY5Y cells. Chem. Biol. Interact. 310, 108688 (2019).","journal-title":"Chem. Biol. Interact."},{"key":"9531_CR60","doi-asserted-by":"crossref","first-page":"60","DOI":"10.4103\/0253-7613.201016","volume":"49","author":"LA Pattanashetti","year":"2017","unstructured":"Pattanashetti, L. A., Taranalli, A. D., Parvatrao, V., Malabade, R. H. & Kumar, D. Evaluation of neuroprotective effect of quercetin with donepezil in scopolamine-induced amnesia in rats. Indian J. Pharmacol. 49, 60\u201364 (2017).","journal-title":"Indian J. Pharmacol."},{"key":"9531_CR61","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.neurobiolaging.2004.09.022","volume":"26","author":"MF Beal","year":"2005","unstructured":"Beal, M. F. Oxidative damage as an early marker of Alzheimer\u2019s disease and mild cognitive impairment. Neurobiol. Aging 26, 585\u2013586 (2005).","journal-title":"Neurobiol. Aging"},{"key":"9531_CR62","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.3233\/JAD-161088","volume":"57","author":"E T\u00f6nnies","year":"2017","unstructured":"T\u00f6nnies, E. & Trushina, E. Oxidative stress, synaptic dysfunction, and Alzheimer\u2019s disease. J. Alzheimer\u2019s. Dis. 57, 1105\u20131121 (2017).","journal-title":"J. Alzheimer\u2019s. Dis."},{"key":"9531_CR63","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s42826-023-00184-1","volume":"39","author":"R Dhapola","year":"2023","unstructured":"Dhapola, R., Kumari, S., Sharma, P. & HariKrishnaReddy, D. Insight into the emerging and common experimental in-vivo models of Alzheimer\u2019s disease. Lab. Anim. Res. 39, 33 (2023).","journal-title":"Lab. Anim. Res."},{"key":"9531_CR64","doi-asserted-by":"crossref","unstructured":"Mahdi, O. et al. WIN55,212-2 Attenuates cognitive impairments in AlCl(3) + d-galactose-induced Alzheimer\u2019s disease rats by enhancing neurogenesis and reversing oxidative stress. Biomedicines 9, 1270 (2021).","DOI":"10.3390\/biomedicines9091270"},{"key":"9531_CR65","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1007\/s10787-023-01287-w","volume":"31","author":"HH Awad","year":"2023","unstructured":"Awad, H. H. et al. Neuromodulatory effect of vardenafil on aluminium chloride\/D-galactose induced Alzheimer\u2019s disease in rats: emphasis on amyloid-beta, p-tau, PI3K\/Akt\/p53 pathway, endoplasmic reticulum stress, and cellular senescence. Inflammopharmacology 31, 2653\u20132673 (2023).","journal-title":"Inflammopharmacology"},{"key":"9531_CR66","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2165\/00002512-200421070-00004","volume":"21","author":"DG Wilkinson","year":"2004","unstructured":"Wilkinson, D. G., Francis, P. T., Schwam, E. & Payne-Parrish, J. Cholinesterase inhibitors used in the treatment of Alzheimer\u2019s disease: the relationship between pharmacological effects and clinical efficacy. Drugs Aging 21, 453\u2013478 (2004).","journal-title":"Drugs Aging"},{"key":"9531_CR67","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1017\/S1041610209990354","volume":"21","author":"J Rodda","year":"2009","unstructured":"Rodda, J., Morgan, S. & Walker, Z. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer\u2019s disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine. Int. Psychogeriatr. 21, 813\u2013824 (2009).","journal-title":"Int. Psychogeriatr."},{"key":"9531_CR68","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1007\/s12035-017-0550-2","volume":"55","author":"C-H Lee","year":"2018","unstructured":"Lee, C.-H. et al. Activation of glucagon-like peptide-1 receptor promotes neuroprotection in experimental autoimmune encephalomyelitis by reducing neuroinflammatory responses. Mol. Neurobiol. 55, 3007\u20133020 (2018).","journal-title":"Mol. Neurobiol."},{"key":"9531_CR69","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.bcp.2014.10.015","volume":"93","author":"A Thompson","year":"2015","unstructured":"Thompson, A. & Kanamarlapudi, V. Agonist-induced internalisation of the glucagon-like peptide-1 receptor is mediated by the G\u03b1q pathway. Biochem. Pharmacol. 93, 72\u201384 (2015).","journal-title":"Biochem. Pharmacol."},{"key":"9531_CR70","doi-asserted-by":"crossref","unstructured":"Shaaban, G., Oriowo, M. & Al-Sabah, S. Rate of homologous desensitization and internalization of the GLP-1 receptor. Molecules 22, 22 (2016).","DOI":"10.3390\/molecules22010022"},{"key":"9531_CR71","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jpha.2019.02.001","volume":"9","author":"AR Pinho","year":"2019","unstructured":"Pinho, A. R. et al. Comparison of ELISA and HPLC-MS methods for the determination of exenatide in biological and biotechnology-based formulation matrices. J. Pharm. Anal. 9, 143\u2013155 (2019).","journal-title":"J. Pharm. Anal."},{"key":"9531_CR72","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.freeradbiomed.2014.07.012","volume":"75","author":"IH Dias","year":"2014","unstructured":"Dias, I. H. et al. Oxidized LDL lipids increase \u03b2-amyloid production by SH-SY5Y cells through glutathione depletion and lipid raft formation. Free Radic. Biol. Med. 75, 48\u201359 (2014).","journal-title":"Free Radic. Biol. Med."},{"key":"9531_CR73","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41392-020-00367-5","volume":"6","author":"LHM Geraldo","year":"2021","unstructured":"Geraldo, L. H. M. et al. Role of lysophosphatidic acid and its receptors in health and disease: novel therapeutic strategies. Signal. Transduct. Target. Ther. 6, 45 (2021).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"9531_CR74","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.bbadis.2012.09.010","volume":"1832","author":"J Shi","year":"2013","unstructured":"Shi, J., Dong, Y., Cui, M. Z. & Xu, X. Lysophosphatidic acid induces increased BACE1 expression and A\u03b2 formation. Biochim. Biophys. Acta 1832, 29\u201338 (2013).","journal-title":"Biochim. Biophys. Acta"},{"key":"9531_CR75","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1002\/jcb.24889","volume":"115","author":"R Awada","year":"2014","unstructured":"Awada, R. et al. Autotaxin downregulates LPS-induced microglia activation and pro-inflammatory cytokines production. J. Cell. Biochem. 115, 2123\u20132132 (2014).","journal-title":"J. Cell. Biochem."},{"key":"9531_CR76","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.bbalip.2018.07.015","volume":"1863","author":"JH Kwon","year":"2018","unstructured":"Kwon, J. H., Gaire, B. P., Park, S. J., Shin, D.-Y. & Choi, J. W. Identifying lysophosphatidic acid receptor subtype 1 (LPA1) as a novel factor to modulate microglial activation and their TNF-\u03b1 production by activating ERK1\/2. Biochim. Biophys. Acta 1863, 1237\u20131245 (2018).","journal-title":"Biochim. Biophys. Acta"},{"key":"9531_CR77","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3389\/fnmol.2020.00058","volume":"13","author":"Y Hao","year":"2020","unstructured":"Hao, Y., Guo, M., Feng, Y., Dong, Q. & Cui, M. Lysophospholipids and their G-coupled protein signaling in Alzheimer\u2019s disease: from physiological performance to pathological impairment. Front. Mol. Neurosci. 13, 58 (2020).","journal-title":"Front. Mol. Neurosci."},{"key":"9531_CR78","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.bbadis.2012.09.010","volume":"1832","author":"J Shi","year":"2013","unstructured":"Shi, J., Dong, Y., Cui, M.-Z. & Xu, X. Lysophosphatidic acid induces increased BACE1 expression and A\u03b2 formation. Biochim. Biophys Acta 1832, 29\u201338 (2013).","journal-title":"Biochim. Biophys Acta"},{"key":"9531_CR79","first-page":"410","volume":"12","author":"YG Wang","year":"2015","unstructured":"Wang, Y. G. & Yang, T. L. Liraglutide reduces oxidized LDL-induced oxidative stress and fatty degeneration in Raw 264.7 cells involving the AMPK\/SREBP1 pathway. J. Geriatr. Cardiol. 12, 410\u2013416 (2015).","journal-title":"J. Geriatr. Cardiol."},{"key":"9531_CR80","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1507\/endocrj.EJ23-0723","volume":"72","author":"L-y Ma","year":"2025","unstructured":"Ma, L. -y. et al. Liraglutide improves cognition function in streptozotocin-induced diabetic rats by downregulating \u03b2-secretase and \u03b3-secretase and alleviating oxidative stress in HT-22 cells. Endocr. J. 72, 285\u2013294 (2025).","journal-title":"Endocr. J."},{"key":"9531_CR81","doi-asserted-by":"crossref","unstructured":"Abo El-Magd, N. F., Ramadan, N. M. & Eraky S. M. Liraglutide attenuates aluminum chloride-induced Alzheimer\u2019s disease in rats by modulating the oxLDL\/LPA\/LPAR1 pathway. figshare. Dataset (2025).","DOI":"10.1038\/s42003-026-09531-z"}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-09531-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-09531-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-09531-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T16:00:52Z","timestamp":1771344052000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-09531-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":81,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9531"],"URL":"https:\/\/doi.org\/10.1038\/s42003-026-09531-z","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"assertion":[{"value":"17 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"262"}}